Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review

Boyd, R. N. and Hays, R. M. (2001). Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. In: Meeting on Clinical Considerations for the Therapeutic Use of Botulinum Toxin Type-A in Cerebral Palsy: an Evidence-Based Examination, Lake Maggiore, Italy, (1-20). June 2000. doi:10.1046/j.1468-1331.2001.00034.x


Author Boyd, R. N.
Hays, R. M.
Title of paper Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review
Conference name Meeting on Clinical Considerations for the Therapeutic Use of Botulinum Toxin Type-A in Cerebral Palsy: an Evidence-Based Examination
Conference location Lake Maggiore, Italy
Conference dates June 2000
Journal name European Journal of Neurology   Check publisher's open access policy
Place of Publication Oxford, United Kingdom
Publisher Wiley-Blackwell
Publication Year 2001
Sub-type Fully published paper
DOI 10.1046/j.1468-1331.2001.00034.x
ISSN 1351-5101
1468-1331
Volume 8
Issue Supplement 5
Start page 1
End page 20
Total pages 19
Language eng
Abstract/Summary Management of children with cerebral palsy (CP) is the focus of considerable resources in many countries, so that evaluation of the efficacy for new and established treatments is imperative. Botulinum toxin type A (BTX-A) is a relatively new method of spasticity management in children with cerebral palsy. It has been the focus of extensive research since its application to cerebral palsy 10 years ago. In a systematic review relating to the management of the lower limb in cerebral palsy 156 papers were identified. These were categorized according to Sackett and the World Health Organisation International Classification of Impairments, Disabilities and Handicaps model. We identified 10 randomized trials evaluating the use of BTX-A in the lower limb in children with cerebral palsy in a systematic review. A meta-analysis showed the pooled risk difference between BTX-A and placebo in three trials was 0.25 (95% CI 0.13, 0.37) and 0.23 (95% CI −0.06, 0.53) for two trials of BTX-A and casting using the physicians rating scale. These represent moderate treatment effects that are dosage-dependent. Outcomes were also compared for function in five studies. The type of evidence for BTX-A was graded by each treatment indication and directions for future research were then drawn from the available evidence.
Keyword Botulinum toxin type A
Cerebral palsy
Evidence
Lower limb
Systematic review
Q-Index Code E1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Conference Paper
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 54 times in Thomson Reuters Web of Science Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 10 Mar 2011, 10:15:28 EST